pI: 5.4888 |
Length (AA): 910 |
MW (Da): 103874 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_130908)
Species | Accession | Gene Product |
---|---|---|
Caenorhabditis elegans | CELE_T05H4.3 | Protein T05H4.3 |
Echinococcus granulosus | EgrG_000740600 | leucine rich repeat containing protein 9 |
Echinococcus multilocularis | EmuJ_000740600 | leucine rich repeat containing protein 9 |
Leishmania braziliensis | LbrM.24.0500 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_240500.1 | Leucine Rich repeats (2 copies)/Leucine rich repeat, putative |
Leishmania infantum | LinJ.24.0500 | hypothetical protein, conserved |
Leishmania major | LmjF.24.0490 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.24.0490 | hypothetical protein, conserved |
Mus musculus | ENSMUSG00000021090 | leucine rich repeat containing 9 |
Neospora caninum | NCLIV_026560 | Cell wall surface anchor family protein, related |
Oryza sativa | 4329947 | Os02g0609900 |
Plasmodium berghei | PBANKA_1012500 | leucine-rich repeat protein |
Plasmodium falciparum | PF3D7_1432400 | leucine-rich repeat protein |
Plasmodium knowlesi | PKNH_0419000 | leucine-rich repeat protein |
Plasmodium yoelii | PY05964 | hypothetical protein |
Plasmodium yoelii | PY05963 | Streptococcus pyogenes AMV253 |
Schistosoma japonicum | Sjp_0013980 | Leucine-rich repeat-containing protein 9, putative |
Schmidtea mediterranea | mk4.000030.18 | |
Trypanosoma brucei gambiense | Tbg972.11.5860 | hypothetical protein, conserved,leucine-rich repeat protein (LRRP), putative |
Trypanosoma brucei | Tb927.11.5190 | leucine-rich repeat protein (LRRP), putative |
Trypanosoma congolense | TcIL3000.11.5400 | leucine-rich repeat protein (LRRP), putative |
Trypanosoma congolense | TcIL3000_0_52890 | leucine-rich repeat protein (LRRP), putative |
Trypanosoma cruzi | TcCLB.504131.70 | hypothetical protein, conserved |
Trichomonas vaginalis | TVAG_050150 | toll, putative |
Trichomonas vaginalis | TVAG_452620 | leucine-rich transmembrane proteins, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.02.2850 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb11.02.2850 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.02.2850 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.02.2850 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.